NPPA exempts Biodeal midazolam nasal spray from price control
In short
NPPA has exempted Biodeal’s midazolam 1.25% w/v nasal spray from price control for five years. The medicine is used as a rescue treatment for emergency seizure care.
The move may help the product commercially, but the report does not give the price or say how much this will change sales. It also does not say when the exemption starts.
What the reporting says
NPPA exempted Biodeal’s indigenously developed midazolam 1.25% w/v nasal spray from price control for five years, according to BusinessLine Companies. The spray is described as a prescription rescue medicine used mainly for emergency treatment of acute repetitive seizures. The report does not state the price, launch date, or whether the exemption changes access or sales.
Why it matters
NPPA exempted Biodeal’s indigenously developed midazolam 1.25% w/v nasal spray from price control for five years. The medicine is a prescription rescue treatment used mainly for emergency acute repetitive seizures. This is a regulatory benefit for the company’s drug, but the available summary does not state the price, commercial impact, or any implementation details.